Humacyte, Inc. (HUMA)
0.776
+0.01
(+0.70%)
USD |
NASDAQ |
Jul 07, 16:00
0.776
0.00 (0.00%)
After-Hours: 20:00
Humacyte EPS Diluted (Quarterly) : -0.089 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.089 |
| December 31, 2025 | -0.1328 |
| September 30, 2025 | -0.1106 |
| June 30, 2025 | -0.2423 |
| March 31, 2025 | 0.279 |
| December 31, 2024 | -0.1649 |
| September 30, 2024 | -0.3283 |
| June 30, 2024 | -0.4755 |
| March 31, 2024 | -0.2947 |
| December 31, 2023 | -0.2423 |
| September 30, 2023 | -0.2513 |
| June 30, 2023 | -0.2197 |
| Date | Value |
|---|---|
| March 31, 2023 | -0.358 |
| December 31, 2022 | -0.0361 |
| September 30, 2022 | -0.2454 |
| June 30, 2022 | 0.3548 |
| March 31, 2022 | -0.1925 |
| December 31, 2021 | 0.4066 |
| September 30, 2021 | -0.7181 |
| June 30, 2021 | -2.894 |
| March 31, 2021 | -3.456 |
| December 31, 2020 | -2.784 |
| September 30, 2020 | -0.0017 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Altimmune, Inc. | -0.1813 |
| Protalix Biotherapeutics, Inc. | 0.2206 |
| Agenus, Inc. | 1.023 |
| Amgen, Inc. | 3.344 |
| Anika Therapeutics, Inc. | -0.3737 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -17.62M |
| Revenue (Quarterly) | 0.495M |
| Total Expenses (Quarterly) | 18.11M |
| Enterprise Value | 188.31M |
| Gross Profit Margin (Quarterly) | -311.7% |
| Profit Margin (Quarterly) | -3.56K% |
| Earnings Yield | -74.06% |
| Normalized Earnings Yield | -85.73 |